Randomised double-blind cross-over trial of proglumide in patients with chronic pain and/or fatigue

Not Applicable

Completed

• Conditions: Respiratory; Signs and Symptoms: Pain; 1. Pain, not elsewhere classified 2. Encephalitis, myelitis and encephalomyelitis

• Registration Number: ISRCTN47564212
• Lead Sponsor: Department of Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2004-09-30
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

40

Exclusion Criteria

Does not match inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary end-point: less fearfulness (as measured by anxiety and activity avoidance) in the proglumide phase of the crossover trial.

Secondary Outcome Measures

Name	Time	Method
Secondary end-points: reduced pain scores during the proglumide phase, increased fearfulness during the ascorbic acid phase in nocebo responders.